Astellas Pharma Inc. (TYO: 4503)

Astellas Pharma Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	292,993	335,687	376,840	315,986	326,128	318,391
Cash & Short-Term Investments	292,993	335,687	376,840	315,986	326,128	318,391
Cash Growth	-12.28%	-10.92%	19.26%	-3.11%	2.43%	2.35%
Accounts Receivable	558,269	534,985	427,965	382,462	343,178	347,042
Other Receivables	12,623	13,051	17,813	21,539	13,984	23,556
Receivables	570,892	548,036	445,778	404,001	357,162	370,598
Inventory	260,214	248,738	174,386	153,072	164,080	151,017
Prepaid Expenses	-	-	-	-	-	11,483
Other Current Assets	78,910	62,269	52,950	50,295	25,218	16,025
Total Current Assets	1,203,009	1,194,730	1,049,954	923,354	872,588	867,514
Property, Plant & Equipment	315,345	293,742	286,459	269,044	264,623	268,600
Long-Term Investments	169,673	163,018	145,028	141,206	146,804	123,154
Goodwill	399,436	418,694	328,411	303,030	284,011	267,510
Other Intangible Assets	1,321,601	1,453,824	562,496	623,431	651,427	738,507
Long-Term Deferred Tax Assets	53,173	45,594	84,169	72,331	54,176	52,876
Other Long-Term Assets	-	1	1	-1	-1	-1
Total Assets	3,462,237	3,569,603	2,456,518	2,332,395	2,273,628	2,318,160
Accounts Payable	161,167	185,193	140,236	130,739	124,777	171,954
Accrued Expenses	-	155,233	143,817	136,553	124,898	76,281
Short-Term Debt	307,257	420,393	75,000	90,000	120,000	326,000
Current Portion of Long-Term Debt	-	51,885	-	50,000	-	-
Current Portion of Leases	-	14,944	13,546	17,730	16,101	18,105
Current Income Taxes Payable	36,045	38,515	5,137	32,388	8,395	43,985
Other Current Liabilities	588,886	419,562	348,298	230,001	198,201	162,383
Total Current Liabilities	1,093,355	1,285,725	726,034	687,411	592,372	798,708
Long-Term Debt	628,571	449,937	54,217	676	80,400	3,142
Long-Term Leases	-	70,756	61,461	55,014	62,163	69,227
Long-Term Deferred Tax Liabilities	23,624	51,346	6,048	5,823	18,161	27,661
Other Long-Term Liabilities	163,106	91,177	75,986	85,937	95,435	92,180
Total Liabilities	1,932,395	1,973,615	948,564	872,087	887,513	1,028,992
Common Stock	103,001	103,001	103,001	103,001	103,001	103,001
Additional Paid-In Capital	183,544	184,070	181,280	179,467	177,830	177,506
Retained Earnings	817,614	809,400	908,158	944,261	953,289	905,851
Treasury Stock	-38,017	-33,783	-25,123	-13,934	-15,377	-7,178
Comprehensive Income & Other	463,700	533,300	340,638	247,513	167,372	109,988
Shareholders' Equity	1,529,842	1,595,988	1,507,954	1,460,308	1,386,115	1,289,168
Total Liabilities & Equity	3,462,237	3,569,603	2,456,518	2,332,395	2,273,628	2,318,160
Total Debt	935,828	1,007,915	204,224	213,420	278,664	416,474
Net Cash (Debt)	-642,835	-672,228	172,616	102,566	47,464	-98,083
Net Cash Growth	-	-	68.30%	116.09%	-	-
Net Cash Per Share	-357.46	-373.53	94.58	55.42	25.54	-52.24
Filing Date Shares Outstanding	1,790	1,793	1,797	1,827	1,853	1,858
Total Common Shares Outstanding	1,790	1,793	1,797	1,827	1,853	1,858
Working Capital	109,654	-90,995	323,920	235,943	280,216	68,806
Book Value Per Share	854.61	890.07	839.26	799.26	748.03	694.03
Tangible Book Value	-191,195	-276,530	617,047	533,847	450,677	283,151
Tangible Book Value Per Share	-106.81	-154.22	343.42	292.19	243.21	152.44

Source: S&P Capital IQ. Standard template. Financial Sources.